Question 1

Are peptides good for muscle building?

Accepted Answer

Some have added measurable mass in people, depending on what you count as muscle. Growth hormone compounds raised lean body mass in randomised human trials. But that scan reading takes in not only muscle but also organs, bone, fluids, and water in fat tissue, so it can rise with no gain in strength. A 2018 review of the secretagogues, compounds that make the pituitary gland release more growth hormone, found that few long-term, rigorously controlled studies have examined them. It noted they might improve lean mass in wasting states and in obese individuals. A 2026 review of six peptides popular with athletes found that 67% of identified publications utilized preclinical animal models. Its verdict was that the claimed benefits remain unsubstantiated by current human trials. So the gain that has been measured is a gain in mass, and mostly in older or ill adults rather than in people who train.

Question 2

What is the strongest peptide for muscle growth?

Accepted Answer

There is no honest way to rank them, because the trials never put them on the same scale. A growth hormone result comes from older men scanned after six months, a collagen result from people lifting weights three times a week, and a BPC-157 result from injured rats. A 2026 critical review of peptide use in sport and bodybuilding names a deeper problem: most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding. Supraphysiological means above the levels the body produces on its own. What can be said is narrower: which compounds were measured for muscle, in whom, for how long, and whether strength moved along with the mass. Those are different questions from which one is strongest.

Question 3

Will I gain muscle on HGH?

Accepted Answer

In older adults, the trials point to a gain in lean body mass, which is not the same thing as a gain in strength. A 2007 systematic review pooled randomised trials of growth hormone in healthy elderly participants and found that overall lean body mass increased by 2.1 kg, with fat mass falling by about the same amount. Its authors still judged the evidence to show small changes in body composition and increased rates of adverse events in those participants. A 2013 review of ageing men reached the same split: lean mass rises by roughly 2 kg, yet there is little evidence that GH treatment improves muscle strength and performance, such as walking speed or the ability to climb stairs. Every one of those trials enrolled people past middle age, so what a younger, trained adult would gain is a separate question. The side effects are taken apart on the HGH safety page, and the approved outcomes on the HGH benefits page.

Question 4

Does HGH make trained athletes stronger?

Accepted Answer

Very little has been measured, and what has been measured did not find a strength gain. A 2002 review set out to ask whether growth hormone improves performance in trained athletes, accepted only randomised, double-blind, placebo-controlled trials, and found that only one study matched the search criteria. The conclusion in that review of human athletes was a single line: there is no evidence of increased muscle strength with HGH in trained athletes. A 2024 umbrella review of systematic reviews reached the same place two decades later, finding that GH alters body composition without providing a strength or performance benefit. In older men doing 16 weeks of heavy resistance exercise, increments in fat-free mass and training-specific maximum voluntary muscle strength were similar in both groups, whether given growth hormone or placebo. The lifting did the work, rather than the hormone.

Question 5

Does MK-677 increase muscle mass?

Accepted Answer

MK-677, also called ibutamoren, is an oral compound that prompts the body to release more growth hormone, and in two randomised trials it raised fat-free mass. In a trial of 24 obese men given it or placebo for eight weeks, fat-free mass increased significantly in the MK-677 treatment group, while total and visceral fat were not significantly changed. The same trial recorded impairment of glucose homeostasis, meaning sugar was handled less well. A two-year trial in 65 healthy adults ranging from 60 to 81 years of age found that fat-free mass increased by 1.1 kg on MK-677 while it slipped on placebo. Its authors wrote that study power was insufficient to evaluate functional end points, so whether that mass made anyone stronger was left open. A related oral compound, capromorelin, was given to 395 older adults, and lean body mass rose 1.4 kg against 0.3 kg, with small gains in walking and, by a year, stair climbing. The wider MK-677 record sits on the MK-677 overview and the MK-677 results page.

Question 6

Do tesamorelin, sermorelin, ipamorelin or CJC-1295 build muscle?

Accepted Answer

Their muscle record is thinner than their reputation. Of these, tesamorelin has the largest randomised record, most of it in people with HIV-associated lipodystrophy, a condition in which body fat is redistributed. A 2026 meta-analysis of five of those trials concluded that it improves body composition, hepatic fat, lean body mass, and IGF-1 levels in that group. A 2003 review of the older work in healthy ageing found that months of use yield an increase in lean body (muscle) mass, but that GHRH treatment has not yielded consistent improvements in physical function. Sermorelin's record among these sources is a 2017 chart review of men given it with two releasing peptides, seeking increases in lean body mass and fat loss, which measured a rise in IGF-1 rather than muscle. For CJC-1295 with ipamorelin, a 2026 primer reports improved maximum tetanic tension in murine models, which were mice whose muscle had been wasted by steroid hormones. That is a test of muscle force in an animal, not a gain in size in a person. See the Tesamorelin overview, the Sermorelin overview, the Ipamorelin overview and the CJC-1295 overview.

Question 7

Does IGF-1 really build muscle?

Accepted Answer

IGF-1 (insulin-like growth factor 1) is what a 2010 review calls the most important mediator of hGH effects. Among the studies behind this page, none gave IGF-1 or its long-acting form, IGF-1 LR3, to healthy adults and then measured their muscle. The approved form, mecasermin, has been available for nearly 20 years for rare cases of growth hormone insensitivity, and a 2009 review judged it unlikely that mecasermin will be useful beyond the orphan indications, meaning rare conditions, for which it was licensed. The same review lists its most frequent side effect as hypoglycemia, a drop in blood sugar, alongside accumulation of body fat. In the 16-week lifting trial in older men described above, there were GH-induced increments in serum IGF-I, yet strength and fat-free mass matched the placebo group. Raising the hormone in the blood and building muscle turned out to be different questions. More is on the IGF-1 overview and the IGF-1 benefits page.

Question 8

Does collagen do anything for muscles?

Accepted Answer

Alongside resistance training it has added a little in several randomised trials. In 53 older men with sarcopenia, the loss of muscle that comes with age, everyone trained three times a week for 12 weeks. Fat-free mass rose 4.2 kg on collagen peptides against 2.9 kg on placebo, and quadriceps strength rose 16.5 against 7.3 newton-metres. In 57 recreationally active young men, collagen produced a significant increase in fat-free mass over placebo, yet type II muscle fibres grew by the same amount in both groups. The trial's authors therefore suspected enhanced passive connective tissue adaptations rather than extra muscle. A 2024 meta-analysis of 19 studies and 768 participants found gains in fat-free mass, muscle mass and maximal strength, graded as low to moderate certainty. That is a real human signal, measured on top of training rather than instead of it. Whether the effect belongs to collagen or to the training is weighed on the Collagen benefits page.

Question 9

Does collagen build muscle the way whey protein does?

Accepted Answer

On the direct measure of muscle building, it does not. Muscle protein synthesis is the rate at which the body lays down new muscle protein, measured with tracers and biopsies. In 22 healthy older women, whey raised it and collagen did not, at rest or after exercise. In young adults given a single serving after lifting, collagen did not further increase myofibrillar or muscle connective protein synthesis rates over placebo, and a week of twice-daily collagen during hard training gave the same null result. One 10-week trial even used collagen peptides as the lower quality placebo, and young adults on a whey-based mix gained more lean mass than those on collagen. The odd result out is a 12-week trial in 97 untrained middle-aged men, where collagen beat placebo on fat-free mass and whey did not differ significantly from either. That disagreement is itself the useful fact: whatever collagen does alongside training, it does not look like what whey does.

Question 10

Is any peptide approved to build muscle?

Accepted Answer

Not for building muscle in a healthy adult, but a few narrow approvals mention muscle. Somatropin, a recombinant growth hormone, is approved in the United States to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting, a steady loss of lean tissue in that illness. Elamipretide, also known as SS-31, carries an indication for the improvement of muscle strength in individuals with Barth syndrome, a rare inherited disease. Anamorelin is not a peptide at all but a ghrelin mimetic, copying the hunger hormone, and it was approved in Japan in January 2021 for cancer cachexia, the wasting that comes with advanced cancer. It increases the appetite and lean body mass of those patients, yet its trials found no statistical significance for walking distance or hand grip strength, the same lean-mass-without-strength pattern. For age-related muscle loss itself, a 2022 review notes that no specific drugs have been approved by the Food and Drug Administration. Each approval belongs to one illness; the SS-31 overview covers the Barth trials.

Question 11

Do GLP-1 drugs cause muscle loss?

Accepted Answer

They take lean mass off along with fat. In a 72-week body-composition substudy of the SURMOUNT-1 trial, participants on tirzepatide lost 33.9% of their fat mass and 10.9% of their lean mass, against 8.2% and 2.6% on placebo. A 2025 network meta-analysis of randomised trials found liraglutide was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass, while the two most potent agents were among the least effective in preserving lean mass. A 2025 review estimated that trial participants lost 10% or more of their muscle mass over 68 to 72 weeks, approximately equivalent to 20 years of age-related muscle loss. A 2024 review adds a caution: lean mass is not muscle mass, and with MRI scans the muscle changes appear to be adaptive, commensurate with what is expected given ageing, disease status, and weight loss achieved. Both readings come from the same trials. The Semaglutide safety page and the Tirzepatide results page carry the compound detail.

Question 12

Can a peptide help you gain muscle and lose fat at the same time?

Accepted Answer

In the trials, lean mass going up while fat came down has turned up mainly with growth hormone in older adults, while the weight-loss peptides take away some of both. In a year-long randomised trial of 193 adults with obesity who had already lost weight on a low-calorie diet, liraglutide alone did not improve physical fitness, and exercise alone led to similar benefits to the combination. Relative strength, meaning strength divided by body weight, fell 7.8% on placebo and rose 3.3% with the combination, because of lower weight and preserved absolute strength. A 2024 review notes that supervised resistance training lasting more than ten weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in adults. In obese mice, pairing semaglutide with bimagrumab, an antibody against the receptor myostatin signals through, led to superior fat mass loss while simultaneously preserving lean mass. That result belongs to mice, and whether it holds in people is a different question.

Question 13

What about follistatin and myostatin blockers?

Accepted Answer

Myostatin is the body's own brake on muscle growth, and one study describes follistatin as a liver-derived inhibitor of the muscle-growth inhibitor myostatin. Given to people, it shows up in these sources only once: a small gene study in a muscle-wasting disease, run together with exercise. A 2018 review noted that an improvement in physical capacity was associated to higher exercise levels, which credits the training more than the gene. The large results are in animals. In a 2024 animal test of a new way to deliver genes, follistatin DNA raised circulating follistatin levels and significantly increased muscle mass and grip strength. A 2013 review was more guarded, writing that Follistatin-like 3 mimetics are less certain because of side effects. And in 60 overweight and obese men, 12 weeks of weight training raised follistatin and lowered myostatin in the blood, so the training itself moved the signal at issue. The Follistatin benefits page goes further.

Question 14

Do BPC-157, MOTS-c or kisspeptin grow muscle?

Accepted Answer

None of them has a human muscle-growth result among the studies behind this page, and the animal work mostly asks a different question. BPC-157 (body protection compound 157) has been studied for repair: in preclinical models it improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries, and a 2019 review notes that the majority of studies have been performed on small rodent models. TB-500, a synthetic fragment of thymosin beta-4, promoted tissue repair in preclinical models, but human orthopaedic data are lacking. Repairing an injured muscle in a rat and adding muscle to a healthy person are different things. MOTS-c, a small peptide made by mitochondria, prevented skeletal muscle atrophy in mice, and male carriers of a natural variant that binds its target less well showed a higher risk of sarcopenia. That is a protection signal rather than growth. For kisspeptin, none of the studies behind this page measured muscle, strength or body composition in anyone given it. Detail is on the BPC-157 benefits page, the TB-500 overview, the MOTS-c overview and the Kisspeptin overview.

Question 15

What peptides do bodybuilders use?

Accepted Answer

The research describes groups of compounds rather than people. A 2026 review of peptides in sport lists three kinds found in bodybuilding: growth hormone releasers such as ipamorelin, copies of the releasing hormone such as CJC-1295 and sermorelin, and short fragments of larger molecules. In human sport, it says, these are promoted for muscle growth, fat metabolism, recovery, and anti-inflammatory effects. The same review says plainly that prevalence studies are lacking, so how many people use them is not known. Over five years, official medicines labs across Europe logged 324 samples from 13 countries, most of them from illegal trade, and the molecules found most often were ibutamoren, ligandrol, ostarine, cardarine and andarine. From limited data, the labs judged most held active doses and some were even overdosed. In tested sport the rule is settled: peptide hormones, growth factors and related substances are prohibited both in- and out-of-competition in section S2 of the anti-doping list.

Question 16

Is a peptide better than creatine or TRT for muscle?

Accepted Answer

No trial among these sources put a peptide against creatine, so that test has not been run, and setting separate trials side by side would compare different people rather than compounds. Creatine's own record is clear. In a 10-week trial in collegiate football players, significantly greater strength improvements were seen with creatine than with placebo. In an eight-week trial in young adults, it significantly enhanced the beneficial effects of resistance training on strength and on muscle size. Testosterone replacement (TRT) comes closer to a real comparison, since one trial ran it against growth hormone head to head. In a trial of 80 healthy older men living at home, given growth hormone, testosterone, both or placebo for six months, lean body mass increased with growth hormone alone and with the pair. Total body fat decreased only in the trial's combination group. A 2026 review says testosterone increases muscle mass and maximal voluntary muscle strength, and strength is the part the growth hormone trials keep missing. A 26-week trial of these hormones in older adults also recorded a high percentage of adverse effects.

Question 17

What are the downsides of using peptides for muscle?

Accepted Answer

The documented harms follow the same compounds that produced the lean-mass results. In a growth hormone trial in older men with low IGF-1, the treated group recorded carpal tunnel syndrome in 10 men, gynaecomastia, meaning breast tissue growth, in 4 and high blood sugar in 3. Those problems clustered in the men whose IGF-1 climbed highest, above 1.0 units/ml. The capromorelin trial in older adults logged fatigue, insomnia and small rises in fasting glucose and insulin resistance. For MK-677, a 2026 scoping review associated it with significant risks including congestive heart failure, and a 2025 case report described raised liver enzymes in a man in his early 30s after two months of use, which settled once he stopped. Who was left out of these trials is set out on the guide to who should not take peptides, with detail on the HGH safety page and the MK-677 safety page.

Peptides for muscle growth: what the trials measured